# Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)

> **NCT03454750** · PHASE2 · COMPLETED · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 143 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer
- 68Ga-PSMA PET/CT Positive

## Interventions

- **DRUG:** 177Lu-PSMA

## Key facts

- **NCT ID:** NCT03454750
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-25
- **Primary completion:** 2024-05-22
- **Final completion:** 2024-05-22
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03454750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03454750, "Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03454750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*